Literature DB >> 26553694

Cardiac Disease Status Dictates Functional mRNA Targeting Profiles of Individual MicroRNAs.

Scot J Matkovich1, Gerald W Dorn2, Tiffani C Grossenheider2, Peter A Hecker2.   

Abstract

BACKGROUND: MicroRNAs are key players in cardiac stress responses, but the mRNAs, whose abundance and translational potential are primarily affected by changes in cardiac microRNAs, are not well defined. Stimulus-induced, large-scale alterations in the cardiac transcriptome, together with consideration of the law of mass action, further suggest that the mRNAs most substantively targeted by individual microRNAs will vary between unstressed and stressed conditions. To test the hypothesis that microRNA target profiles differ in health and disease, we traced the fate of empirically determined miR-133a and miR-378 targets in mouse hearts undergoing pressure overload hypertrophy. METHODS AND
RESULTS: Ago2 immunoprecipitation with RNA sequencing (RNA-induced silencing complex sequencing) was used for unbiased definition of microRNA-dependent and microRNA-independent alterations occurring among ≈13 000 mRNAs in response to transverse aortic constriction (TAC). Of 37 direct targets of miR-133a defined in unstressed hearts (fold change ≥25%, false discovery rate <0.02), only 4 (11%) continued to be targeted by miR-133a during TAC, whereas for miR-378 direct targets, 3 of 32 targets (9%) were maintained during TAC. Similarly, only 16% (for miR-133a) and 53% (for miR-378) of hundreds of indirectly affected mRNAs underwent comparable regulation, demonstrating that the effect of TAC on microRNA direct target selection resulted in widespread alterations of signaling function. Numerous microRNA-mediated regulatory events occurring exclusively during pressure overload revealed signaling networks that may be responsive to the endogenous decreases in miR-133a during TAC.
CONCLUSIONS: Pressure overload-mediated changes in overall cardiac RNA content alter microRNA targeting profiles, reinforcing the need to define microRNA targets in tissue-, cell-, and status-specific contexts.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  Ago2 protein; RNA; RNA-induced silencing complex; gene expression; messenger; microRNAs; regulation

Mesh:

Substances:

Year:  2015        PMID: 26553694      PMCID: PMC4681654          DOI: 10.1161/CIRCGENETICS.115.001237

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  48 in total

Review 1.  Developing microRNA therapeutics.

Authors:  Eva van Rooij; Angela L Purcell; Arthur A Levin
Journal:  Circ Res       Date:  2012-02-03       Impact factor: 17.367

2.  RISC RNA sequencing for context-specific identification of in vivo microRNA targets.

Authors:  Scot J Matkovich; Derek J Van Booven; William H Eschenbacher; Gerald W Dorn
Journal:  Circ Res       Date:  2010-10-28       Impact factor: 17.367

3.  A human 3' miR-499 mutation alters cardiac mRNA targeting and function.

Authors:  Gerald W Dorn; Scot J Matkovich; William H Eschenbacher; Yan Zhang
Journal:  Circ Res       Date:  2012-02-28       Impact factor: 17.367

4.  MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway.

Authors:  Zhenwei Pan; Xuelin Sun; Hongli Shan; Ning Wang; Jinghao Wang; Jinshuai Ren; Shuya Feng; Liangjun Xie; Chunying Lu; Ye Yuan; Yang Zhang; Ying Wang; Yanjie Lu; Baofeng Yang
Journal:  Circulation       Date:  2012-07-18       Impact factor: 29.690

Review 5.  Differential expression of microRNAs in different disease states.

Authors:  Maha Abdellatif
Journal:  Circ Res       Date:  2012-02-17       Impact factor: 17.367

6.  Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

Authors:  Rusty L Montgomery; Thomas G Hullinger; Hillary M Semus; Brent A Dickinson; Anita G Seto; Joshua M Lynch; Christianna Stack; Paul A Latimer; Eric N Olson; Eva van Rooij
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

7.  A cardiac microRNA governs systemic energy homeostasis by regulation of MED13.

Authors:  Chad E Grueter; Eva van Rooij; Brett A Johnson; Susan M DeLeon; Lillian B Sutherland; Xiaoxia Qi; Laurent Gautron; Joel K Elmquist; Rhonda Bassel-Duby; Eric N Olson
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

8.  Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy.

Authors:  Scot J Matkovich; Yuanxin Hu; William H Eschenbacher; Lisa E Dorn; Gerald W Dorn
Journal:  Circ Res       Date:  2012-06-29       Impact factor: 17.367

9.  MicroRNA-24 regulates cardiac fibrosis after myocardial infarction.

Authors:  Jue Wang; Weicong Huang; Ruixia Xu; Yu Nie; Xiaoqing Cao; Jiang Meng; Xiuqin Xu; Shengshou Hu; Zhe Zheng
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

10.  Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.

Authors:  Ioannis Karakikes; Antoine H Chaanine; Soojeong Kang; Bertrand N Mukete; Dongtak Jeong; Shihong Zhang; Roger J Hajjar; Djamel Lebeche
Journal:  J Am Heart Assoc       Date:  2013-04-23       Impact factor: 5.501

View more
  3 in total

1.  Molecular mechanisms in vascular injury induced by hypertension: Expression and role of microRNA-34a.

Authors:  Siguan Liu; Fanfan Yi; Wenwei Cheng; Xin Qu; Chunting Wang
Journal:  Exp Ther Med       Date:  2017-09-27       Impact factor: 2.447

2.  Metabolomic and transcriptomic signatures of chemogenetic heart failure.

Authors:  Fotios Spyropoulos; Andrea Sorrentino; Jiska van der Reest; Peiran Yang; Markus Waldeck-Weiermair; Benjamin Steinhorn; Emrah Eroglu; Seyed Soheil Saeedi Saravi; Paul Yu; Marcia Haigis; Helen Christou; Thomas Michel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-01-28       Impact factor: 4.733

3.  The Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent.

Authors:  Joep E C Eding; Charlotte J Demkes; Joshua M Lynch; Anita G Seto; Rusty L Montgomery; Hillary M Semus; Aimee L Jackson; Marc Isabelle; Stefano Chimenti; Eva van Rooij
Journal:  Mol Ther       Date:  2017-02-12       Impact factor: 11.454

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.